Holen Sie sich die Stockscreener-App
1.16
2.52%
-0.03
Handel nachbörslich:
1.16
Schlusskurs vom Vortag:
$1.19
Offen:
$1.2
24-Stunden-Volumen:
136.78K
Relative Volume:
0.05
Marktkapitalisierung:
$12.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.66M
KGV:
-0.1422
EPS:
-8.156
Netto-Cashflow:
$-11.09M
1W Leistung:
+6.42%
1M Leistung:
+0.87%
6M Leistung:
-53.41%
1J Leistung:
-31.36%
1-Tages-Spanne:
$1.1401
$1.20
1-Wochen-Bereich:
$1.10
$1.22
52-Wochen-Spanne:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Vergleichen Sie PHIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.16 | 12.81M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
Why Phio Pharmaceuticals Corp. stock is a value investor pickShort Setup & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Is Phio Pharmaceuticals Corp. stock a contrarian buyWeekly Earnings Recap & Fast Gain Swing Trade Alerts - ulpravda.ru
Will Phio Pharmaceuticals Corp. stock benefit from infrastructure spendingJuly 2025 Setups & Safe Entry Trade Signal Reports - ulpravda.ru
Why retail investors pile into Phio Pharmaceuticals Corp. stock2026 world cup usa national team semifinals defensive leaders low block defense odds analysis insights - ulpravda.ru
Insider Buying: Robert Bitterman Acquires Additional Shares of P - GuruFocus
PHIO News Today | Why did Phio Pharmaceuticals stock go up today? - MarketBeat
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Momentum Shift: Can Phio Pharmaceuticals Corp stock beat analyst upgradesBuy Signal & Reliable Breakout Forecasts - moha.gov.vn
Best Value Stocks to Buy for April 23rd - MSN
Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated - MSN
Phio Pharmaceuticals chairman Bitterman buys $5,100 in stock By Investing.com - Investing.com South Africa
Phio Pharmaceuticals chairman Bitterman buys $5,100 in stock - Investing.com
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series - TMX Newsfile
MSN Money - MSN
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - TMX Newsfile
Phio To Commence A Toxicology Study For PH-762; Initiatives Underway For A Viable Product In 2026 - Nasdaq
Phio to begin FDA-required toxicology study for cancer drug PH-762 - Investing.com Nigeria
Phio Advances PH-762 With FDA-Backed Toxicology Study - TipRanks
Phio to begin FDA-required toxicology study for cancer drug PH-762 By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Corp to begin toxicology study for PH-762 before human trialsSEC filing - marketscreener.com
Phio Pharmaceuticals (NASDAQ: PHIO) details FDA-cleared PH-762 tox study plan - Stock Titan
Phio Pharmaceuticals Corp Advances PH-762 Drug Development - TradingView — Track All Markets
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 - TMX Newsfile
Risk Off: Why Phio Pharmaceuticals Corp. stock appeals to dividend seekersJuly 2025 Decliners & Growth Focused Stock Pick Reports - Улправда
How Phio Pharmaceuticals Corp. stock benefits from strong dollarDip Buying & Detailed Earnings Play Alerts - Улправда
How Phio Pharmaceuticals Corp. stock responds to policy changesWeekly Trend Recap & Reliable Intraday Trade Alerts - Улправда
Can Phio Pharmaceuticals Corp. (44R1) stock sustain breakout momentum - DonanımHaber
How Phio Pharmaceuticals Corp. stock reacts to Fed rate cutsJuly 2025 Macro Moves & Weekly Setup with ROI Potential - DonanımHaber
Why Phio Pharmaceuticals Corp. stock appeals to dividend seekersQuarterly Trade Review & Risk Managed Investment Strategies - Улправда
How resilient is Phio Pharmaceuticals Corp. stock in market downturns2025 Market Sentiment & Weekly High Momentum Picks - Улправда
New Strong Buy Stocks for May 28th - MSN
We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run - MSN
EBIT per share of Phio Pharmaceuticals Corp. – BER:44R1 - TradingView
Will Phio Pharmaceuticals Corp. (44R1) stock beat revenue estimatesMarket Performance Summary & Risk Managed Trade Strategies - Newser
How Phio Pharmaceuticals Corp. (44R1) stock reacts to fiscal policiesJuly 2025 Update & AI Optimized Trading Strategy Guides - Newser
How Phio Pharmaceuticals Corp. (44R1) stock reacts to new regulationsJuly 2025 Selloffs & High Yield Equity Trading Tips - Newser
What technical patterns form on Phio Pharmaceuticals Corp. (44R1) stock chartsJuly 2025 Selloffs & High Yield Equity Trading Tips - Newser
Will Phio Pharmaceuticals Corp. (44R1) stock rise with strong economyWeekly Trend Summary & Weekly High Return Stock Opportunities - Newser
Phio Pharma (PHIO) Stock Analysis Report | Financials & Insights - Benzinga
How Phio Pharmaceuticals Corp. (44R1) stock compares with market leadersPortfolio Update Summary & Reliable Entry Point Trade Alerts - Newser
What insider trading reveals about Phio Pharmaceuticals Corp. stockProfit Target & Verified Swing Trading Watchlists - Newser
Can Phio Pharmaceuticals Corp. stock continue upward trendMarket Sentiment Report & Real-Time Volume Analysis - Newser
Phio Pharmaceuticals Completes Enrollment for PH-762 Trial - MSN
TARC Limited Earnings Review What Investors Need to KnowMid Cap Growth Trends & Free Risk Assessment and Control - earlytimes.in
Phio Pharmaceuticals Completes Enrollment in Phase 1b Trial of PH-762 - TradingView — Track All Markets
Phio Pharmaceuticals Corp. Announces Completion of Enrollment in Phase 1B Clinical Trial of Intasyl Sirna Lead Compound Ph-762 - marketscreener.com
Phio completes enrollment in Phase 1b trial of skin cancer therapy - Investing.com Australia
Phio completes enrollment in Phase 1b trial of skin cancer therapy By Investing.com - Investing.com South Africa
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phio Pharmaceuticals Corp-Aktie (PHIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):